| |
Cell therapy trials are complex and successfully operationalizing these studies requires careful consideration of the interplay between the patient journey and vein-to-vein logistics workflow. Download our guide to learn how to optimize this process, including key steps in study execution and improving study retention.
Premier Research. Built for Biotech℠
|
|
Today's Big NewsJun 23, 2023 |
| By Nick Paul Taylor Roche has bowed out of the race to develop an antisense oligonucleotide (ASO) for Angelman syndrome. After getting a look at early efficacy data, the Swiss drugmaker opted against advancing the candidate, switching its Angelman focus to another asset and leaving the ASO space to Biogen, Ionis and Ultragenyx. |
|
|
|
By James Waldron Barely six months after launching, Paragon Therapeutics’ first spinout has set its sights on the public markets as well as taking on some of the biggest names in immunology and inflammation. |
By James Waldron Laying off “substantially all” your workforce is normally a sign that a biotech is in a death spiral, but Acasti Pharma’s CEO is insistent that the move has “energized” the company as it gears up for a phase 3 study of its lead asset. |
Sponsored by Invest Puerto Rico Puerto Rico is becoming the best place in the world to conduct R&D activities for emerging technologies. Could your organization maximize growth potential by capitalizing on Puerto Rico’s unique tax incentives & culture of innovation? |
By Nick Paul Taylor The Alphabet spinoff SandboxAQ has signed up AstraZeneca and Sanofi as users of its drug discovery and development tools. Fresh from raising $500 million, the startup has secured the big-name customers for a newly established biopharma molecular simulation division that aims to accelerate R&D. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Max Bayer,Gabrielle Masson When Bayer named former Roche pharma chief Bill Anderson as its new CEO, it was clear the company would be leaning into its pharmaceutical business focus moving forward. That’s been further cemented with the promotion of Sebastian Guth as head of the company’s U.S. operations. |
By Teresa Carey This week on "The Top Line," we discuss the most expensive drugs in the U.S., plus Eli Lilly's recent acquisition, the latest company to challenge the Inflation Reduction Act, and the rest of the week's headlines. |
By Zoey Becker After the FDA said it needed "modest additional time" to review the therapy, the agency has ultimately approved the Duchenne muscular dystrophy gene therapy under the accelerated approval pathway. It's now branded as Elevidys. |
By Andrea Park The next year is set to be a busy one for Allurion: Not only is the weight-loss technology maker planning to go public this summer, but it has also now tapped Medtronic to help bring its technology to even more healthcare providers and patients around the world. |
By Angus Liu Even after a second application attempt, Intercept’s Ocaliva wasn’t the fatty liver disease breakthrough that the company had hoped it would be. Intercept is now swinging into restructuring mode, and the NASH baton passes on to Madrigal Pharma. |
By Heather Landi Last month, CVS Health announced plans to sunset its research recruitment business unit just two years after its launch. What does CVS' exit spell out for rival Walgreens and other new players in the clinical trials space? |
By Angus Liu AstraZeneca has reportedly worked out a contingency plan to spin out its China business amid increasing geopolitical risks. The British pharma is still forming collaborations in the country, the latest being an R&D pact focused on hypercholesterolemia. Takeda is experiencing a shortage of ADHD med Vyvanse. And more. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss the most expensive drugs in the U.S., plus Eli Lilly's recent acquisition, the latest company to challenge the Inflation Reduction Act, and the rest of the week's headlines. |
|
|---|
|
|
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| eBookSee how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
